Hepatitis C

Norah Terrault, MPH, MD, discusses gaps in treatment in people who are infected with hepatitis C virus and what steps clinicians should take when treating these patients.

At 12 weeks post treatment per protocol analysis with 8 weeks of glecaprevir/pibrentasvir treatment, patients with hepatitis C virus genotypes 1, 2, 4, 5 and 6 achieved a sustained virologic response.

Investigators praised the excellent effectiveness of both therapies, but advised care regarding the increased odds of adverse events requiring hospitalizations.

A new meta-analysis finds people who were recently incarcerated face significantly higher risks of contracting hepatitis C and HIV infection.

Treatment regimens comprised of DCV+SOF±RBV and VEL/SOF+RBV offer similar cure rates among HCV patients with genotypes 2 and 3.

A new study found that almost all humans have a less active form of interferon lambda 4, a fact that leaves them vulnerable to HCV.

How the therapy is proving capable of giving patients the opportunity to slow down disease progression, while potentially increasing the health outcomes of patients and saving money.

Mathematical modeling projects that Australia could achieve World Health Organization targets for elimination of HCV in a decade. What can the US learn from their efforts?

New data suggest hepatitis C infection, but not hepatitis B infection, increases the prevalence of diabetes in patients who undergo kidney transplants.

People who are addicted to drugs face a higher risk of contracting HCV. Yet, a new study suggests the majority teens who are addicted to opioids don’t get screened for the virus.

Individuals with hepatitis C infection who use cannabis were also found to have lower total healthcare costs than non-users.

New research suggests that the choice of a direct-acting antiviral regimen does not appear to affect liver cancer risk in patients with HCV.

Kenneth Sherman, MD, PhD, discusses prevention measures for hepatitis B, managing co-infections of HIV and HCV, and recent developments to HCV screening processes

This observational data could serve an important role in pharmacoepidemiologic studies that would assess the overall benefit and risks of modern HCV therapies, namely direct-acting antivirals.

Approximately 30% of annual HIV infections are caused by the subset of individuals unaware of their serostatus, and HCV rates have nearly tripled since 2011.

Elbasvir/Grazoprevir has performed well in clinical trials, even among patients with HIV and other coinfections.

New research says it’s medically possible to use HCV-positive patients as liver donors. Now, a new study finds it’s also cost-effective.

The results of a recent study indicate that combination DAA regimens that include sofosbuvir are effective for achieving SVR in patients with chronic hepatitis C virus and compensated liver cirrhosis.

Direct-acting antivirals have been a life-changing breakthrough for patients with chronic hepatitis C virus infection. However, the high cost of the drugs has led many patients down a path of appeals and battles with insurers.

Patients whose direct-acting antiviral treatment failed are finding hope in a new combination of 3 existing hepatitis C virus drugs.

Use of this new approach suggests that HCV infection burden in New York City has been underestimated in populations considered high-risk for HCV, and that HCV transmission has increased among young adults in the city.

The study authors state these data can be used to develop a tailored approach to the elimination of hepatitis C virus infection, worldwide.

The dual use of ribavirin and direct-acting antivirals during treatment for hepatitis C virus was found to independently predict decline in mental health-related quality-of-life.

The results of a new study indicate that most physicians are not following the CDC’s recommendation to screen all Baby Boomers for hepatitis C.

New research finds patients hospitalized for alcohol dependence have lower rates of survival if they are also infected with hepatitis C.

The second member of the FDA-approved thrombopoietin receptor agonist drug class was proven efficacious and safe in a pair of phase 3 trials.

The 2 assays from Ortho Clinical Diagnosis consolidates the company's package of devices and systems designed to give patients frequent diagnoses.

A new analysis suggests the benefits of universal HCV screening would outweigh the significant costs.

A vaccine for hepatitis C would likely not eliminate the risk of transmission, but a new study suggests it would dramatically reduce transmission rates among drug users from 90% to 25% or less.

SYMTUZA has been approved by the FDA based on the data of a pair of 48-week pivotal phase 3 trials which showed the non-inferiority safety and efficacy of the drug versus a controlled regimen.